Rodríguez-Moyado H

Language: Spanish
References: 17
Page: 39-41
PDF size: 40.15 Kb.

ABSTRACT

Problems in transfusional medicine are common. We require evidencebased diagnostic and therapeutic progress information that may allow to find adequate solutions. Controlled random studies are scasce in our field, since transfusion needs are often critical. In 1818 Blundell reported satisfactory transfusion results in post-partum hemorrhage in several women. During the world wars, soldiers with severe wounds were saved with blood transfusion, as evidence of its efficacy. After 1945 hemotherapy was performed on children and adults. Other milestones in blood transfusion include the discovery of Dausset’s 1954 HLA system, the 1960’s blood component separation in plastic bags and Blunberg´s 1968, discovery of the Australian hepatitis B antigen. In 1947, 10g Hb/dL was proposed as desirable threshold for surgery. This idea still persists 40 years later. In 1999, Hébert ad colleges found evidence of successful transfusions with 7g Hb/dL in critical patients. The blood transfusion risks of the patient´s viral contaminations are continuously decreasing due to more sensitive and specific tests. Inactivation of blood pathogen microorganisms is another resource for transfusion security. Nevertheless, risks of blood identity confusion due to incompatible transfusions still persists. Post-operatory immunomodulation has been used in orthopedic surgery. Progress in donor selection methodology and conditioning of blood components, will favor the prevention of receptor transfusion risks.

REFERENCES

1. Wintrobe MM. Blood Pure and Eloquent. McGraw Hill Book Company. 1a ed. New York, USA, 1980.

2. Genetet B, Mannoni P. La transfusión. Ediciones Toray S.A. 1ª ed. Barcelona, España, 1980.

3. Spiece BD. Risk of transfusión: outcome focus. Transfusion 2004; 44: december suppl.: 4S.

4. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al, A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. N Eng. J. Med. 1999;340:409-417.

5. Dausset et. Nenna A. Présence d´une leuco-agglutinine dans le serún d´un cas d´aggranulocytose chronique. Compt Rendu Soc Biol 1952 ; 146 : 1539-1541.

6. Bux J .Transfusion related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sanguinis 2005;89:1-10.

7. Witt CS et Christiansen FT, The relevance of natural killer cell human leucyte antigen epitopes and killer immunoglobulin-like receptors in bone marrow transplantation Vox. Sanguinis 2006;90:10-20.

8. Blunberg BF, Suttnick AI, and London WT. Hepatitis and leukaemia their relation to Australian antigen. Bull NY Acad Med 1968;44:1566.

9. Council of Europe Expert Committee in blood transfusion study group on pathogen inactivation of labile blood components: pathogen inactivation of labile components Transfusion Medicine 2001;11:149-175.

10. Miale JB, Laboratory Medicine Hematology. The C.V. Mosby Company 3th. ed. San Louis Mo., USA 1967.

11. Blajchman MA. Landmark studies that have changed the practice of transfusion medicine 2005;45:1523-1550.

12. Rodríguez-Moyado H. Medicina sin Transfusiones Rev. Med. IMSS 2005;43:229-235.

13. Moonen AFM, Knoovs NT, van Os JJ, Verburg AD and Pilot P. Retransfusion of filtered shed blood in primary total hip and knee arthroplasty: a prospective and randomized clinical trial. Transfusion 2007;47:379-384.

14. Klein HG. Transfusion associated graft – versus – host disease: less fresh blood and more gray (Gy) for and aging population. Transfusion 2006; 46: 878-880

15. Högman C, Meryman HT. Red Blood cells intended for transfusion: quality criteria revisited. Transfusion 2006;46:137-142.

16. Brunstein CG, et Wagner JE. Cord blood transplantation for adults. Vox Sanguinis 2006;91:195-205.

17. Levy JH. Hemostatic agents. Transfusión 2004;44:58S.